Signal Transduction and Chemical Biology Research Program

项目002-信号转导与化学生物学研究 项目总结/摘要 信号转导和化学生物学研究计划（ST）从事基础癌症研究 了解患者和癌症特异性信号网络和细胞周期的重新布线，以及如何 干/祖细胞可塑性和异质性有助于肿瘤发生。这些信息用于识别 新的目标，可能是未来药物发现工作的重点。因此，科技的首要目标是 开发新的和/或测试针对癌症起始和进展的重要驱动因素的小分子先导物， 帮助优化药物的"线索"，使ST的发现可以作为新的癌症转化为临床 干预措施。ST领导层的主要作用是确保临床研究者之间的沟通， 以人口为基础的研究人员和基础科学家，以确保潜在的翻译研究结果得到探讨。 ST领导层和范德比尔特-英格拉姆癌症中心（VICC）赞助会议和务虚会，以确保 基础科学发现的传播是强大的。计划目标将通过以下方式实现：1）执行 在单细胞生物学，干细胞和信号网络的前沿研究，以确定关键目标，赋予 人类癌症的选择性依赖性; 2）促进化学生物学的前沿研究， 开发新的癌症治疗方法; 3）促进计划成员之间的互动， 加速发现，指导初级教师，促进与临床项目的合作，促进技术 如scRNA-seq、超分辨率显微镜、质谱细胞术和PROTACS，并与VICC密切合作 共享资源，以开发用于癌症发现的新仪器。共有44名项目成员， 13个部门和4所学校，同行评审资金总额为1100万美元，NCI占39%（430万美元）。 在372份出版物中，15%是方案内出版物，34%是方案间出版物。成员国也有115个 与其他NCI指定癌症中心的研究者合作出版。

PROJECT 002– SIGNAL TRANSDUCTION AND CHEMICAL BIOLOGY RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The Signal Transduction and Chemical Biology Research Program (ST) pursues fundamental cancer research to understand patient- and cancer-specific rewiring of signaling networks and the cell cycle, and how stem/progenitor cell plasticity and heterogeneity contribute to tumorigenesis. This information is used to identify new targets that could be the focus of future drug discovery efforts. Accordingly, an overarching goal of ST is to develop novel and/or test small molecule leads against important drivers of cancer initiation and progression and aid the optimization of `leads' to drugs so that ST discoveries can be translated to the clinic as new cancer interventions. The major role of ST leadership is to ensure communication between clinical investigators, population-based researchers and basic scientists to ensure that potentially translatable findings are explored. ST leadership and Vanderbilt-Ingram Cancer Center (VICC) sponsor meetings and retreats to ensure that communication of the basic science discoveries is robust. Program goals will be accomplished by: 1) performing cutting-edge research in single cell biology, stem cells and signaling networks, to identify key targets that confer selective dependencies in human cancers; 2) promoting cutting edge research in chemical biology and development of new cancer therapeutics; and 3) stimulating interactions among the Program membership to accelerate discovery, mentor junior faculty, foster collaborations with clinical programs, promote technologies such as scRNA-seq, super-resolution microscopy, mass cytometry and PROTACS, and work closely with VICC Shared Resources to develop new instrumentation for cancer discovery. There are 44 program members from 13 departments and four schools with $11M in total peer-reviewed funding and NCI making up 39% ($4.3M). Out of 372 publications, 15% are intra-programmatic and 34% are inter-programmatic. Members also have 115 collaborative publications with investigators at other NCI-designated cancer centers.